Company profile
NRx Pharmaceuticals, Inc.
NASDAQ: NRXP · Healthcare · Biotechnology
#859 of 1,422 Healthcare companies by revenue
EA Score
24DFH 27DQ 13GM —SS 49
v0.1 · 55/100 weight · provisional
↑ Piotroski F, market scale · ↓ disclosure history, net margin
Methodology →Revenue TTM
$2.3M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$28.6M
Employees
29
as of 2026-08-19
Market cap
$59.5M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.2M$1.2M2025
Net income-$28.6M-$28.6M2025
Operating income-$16.2M-$16.2M2025
Total assets$13.0M$13.0M2025
Liabilities$28.9M$28.9M2025
Equity-$15.9M-$15.9M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Therapy100%
By geography
Not disclosed.
The read
What is NRx Pharmaceuticals, Inc.’s revenue?
NRx Pharmaceuticals, Inc. booked $1.2M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -2336.5% net margin.
Peers · Healthcare
VistaGen Therapeutics, Inc.46DBaudax Bio, Inc.——SeaStar Medical Holding Corporation30DLongeveron Inc.30DSOHM, Inc.61CPeoplesway.com Inc.——Neighbors
New Castle →Key facts
CEOJonathan C. Javitt
SectorHealthcare
IndustryBiotechnology
HeadquartersWilmington, DE
ExchangeNASDAQ: NRXP
Employees29
IPO date2017-12-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.